tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Buy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy
RatingsBuy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy
2d ago
IVA
Inventiva price target raised to $24 from $20 at H.C. Wainwright
PremiumThe Fly
Inventiva price target raised to $24 from $20 at H.C. Wainwright
2d ago
IVA
Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
PremiumRatings
Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
10d ago
IVA
Inventiva management to meet with Piper Sandler
PremiumThe Fly
Inventiva management to meet with Piper Sandler
10d ago
IVA
Inventiva positioned as next acquisition target, says H.C. Wainwright
PremiumThe Fly
Inventiva positioned as next acquisition target, says H.C. Wainwright
23d ago
IVA
Buy Rating for Inventiva: Lanifibranor’s Promising Role in Metabolic Disease Treatment
PremiumRatingsBuy Rating for Inventiva: Lanifibranor’s Promising Role in Metabolic Disease Treatment
24d ago
IVA
Inventiva assumed with a Buy at H.C. Wainwright
Premium
The Fly
Inventiva assumed with a Buy at H.C. Wainwright
1M ago
IVA
Inventiva price target raised to $13 from $9 at Guggenheim
Premium
The Fly
Inventiva price target raised to $13 from $9 at Guggenheim
1M ago
IVA
Inventiva initiated with an Overweight at Piper Sandler
PremiumThe Fly
Inventiva initiated with an Overweight at Piper Sandler
2M ago
IVA
Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating
PremiumRatings
Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating
2M ago
IVA
Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating
PremiumRatings
Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating
2M ago
IVA
Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed
PremiumThe Fly
Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed
3M ago
IVA
Inventiva receives $10M milestone payment from Chia Tai-Tianqing Pharmaceutical
PremiumThe FlyInventiva receives $10M milestone payment from Chia Tai-Tianqing Pharmaceutical
3M ago
IVA
Inventiva’s Lanifibranor: A Promising Investment in the MASH Space with Strong Phase III Progress and Financial Backing
Premium
Ratings
Inventiva’s Lanifibranor: A Promising Investment in the MASH Space with Strong Phase III Progress and Financial Backing
4M ago
IVA
Inventiva describes share repurchase covered by Kepler Chevreux agreement
Premium
The Fly
Inventiva describes share repurchase covered by Kepler Chevreux agreement
5M ago
IVA
Inventiva’s Strategic Milestones and Promising Outlook Drive Buy Rating
PremiumRatings
Inventiva’s Strategic Milestones and Promising Outlook Drive Buy Rating
6M ago
IVA
Inventiva price target lowered to $9 from $12 at Guggenheim
PremiumThe Fly
Inventiva price target lowered to $9 from $12 at Guggenheim
6M ago
IVA
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright
PremiumThe Fly
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright
6M ago
IVA
Inventiva’s Strategic Advancements and Financial Strength Bolster Buy Rating
PremiumRatings
Inventiva’s Strategic Advancements and Financial Strength Bolster Buy Rating
6M ago
IVA
Inventiva’s Strategic Advancements and Financial Positioning Drive Buy Rating
PremiumRatingsInventiva’s Strategic Advancements and Financial Positioning Drive Buy Rating
6M ago
IVA
Inventiva’s Promising Future: Buy Rating Backed by Phase III Milestone and Financial Stability
Premium
Ratings
Inventiva’s Promising Future: Buy Rating Backed by Phase III Milestone and Financial Stability
6M ago
IVA
Inventiva SA Earnings Call: Positive Outlook Amid Challenges
Premium
Company Announcements
Inventiva SA Earnings Call: Positive Outlook Amid Challenges
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >